Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: A decision analysis for the U.S. preventive services task force

Annals of Internal Medicine

Volumn 164, Issue 12, 2016, Pages 777-786

  Dehmer, Steven P ^a   Maciosek, Michael V ^a   Flottemesch, Thomas J ^b   LaFrance, Amy B ^a   Whitlock, Evelyn P ^c  

^a HEALTHPARTNERS INSTITUTE   (United States)

^b IBM WATSON HEALTH   (United States)

^c PATIENT CENTERED OUTCOMES RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CASE FATALITY RATE; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIFE EXPECTANCY; LOW DRUG DOSE; MEDICAL DECISION MAKING; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SECONDARY PREVENTION; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); ADULT; AGED; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; DECISION SUPPORT SYSTEM; FEMALE; MALE; MIDDLE AGED; RISK ASSESSMENT;

ADULT; AGED; ANTICARCINOGENIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PRIMARY PREVENTION; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; STROKE;

EID: 84975275161     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-2129     Document Type: Article

References (56)

1. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86. [PMID: 11786451]
2. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. [PMID: 19482214] doi: 10.1016/S0140-6736(09)60503-1
3. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007;146:361-4. [PMID: 17339621]
4. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396-404. [PMID: 19293072]
5. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-13. [PMID: 16418466]
6. Krantz MJ, Berger JS, Hiatt WR. An aspirin a day: are we barking up the wrong willow tree? [Editorial]. Pharmacotherapy. 2010;30: 115-8. [PMID: 20099985] doi: 10.1592/phco.30.2.115
7. Gaziano JM, Greenland P. When should aspirin be used for prevention of cardiovascular events? [Editorial]. JAMA. 2014;312: 2503-4. [PMID: 25402671] doi: 10.1001/jama.2014.16047
8. Pignone M. Aspirin for primary prevention: a challenging decision [Editorial]. J Am Heart Assoc. 2014;3. [PMID: 25146710] doi: 10.1161/JAHA.114.001254
9. Guirguis-Blake JM, Evans CV, Senger CA, Rowland MG, O'Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 131. AHRQ Publication No. 13-05195-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. [PMID: 26491760]
10. Chubak J, Kamineni A, Buist DSM, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 133. AHRQ Publication No. 15-05228-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. [PMID: 26491758]
11. Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T. Aspirin Use in Adults: Cancer, All-Cause Mortality and Harms. A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 132. AHRQ Publication No. 13-05193-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. [PMID: 26491756]
12. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:804-13. doi: 10.7326/M15-2113
13. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, et al. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:814-25. doi: 10.7326/M15-2117
14. Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016;164:826-35. doi: 10.7326/M15-2112
15. Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836-45. doi: 10.7326/M16-0577
16. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2935-59. [PMID: 24239921] doi: 10.1016/j.jacc.2013.11.005
17. Annual estimates of the resident population by sex, race alone, and Hispanic origin for counties: April 1, 2010 to July 1, 2011. Washingon, DC: U.S. Census Bureau; 2011.
18. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: NHANES 2001-2002. Hyattsville, MD: National Center for Health Statistics; 2004. Accessed at wwwn.cdc.gov/nchs/nhanes/search/nhanes01-02.aspx on 14 March 2016.
19. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: NHANES 2003-2004. Hyattsville, MD: National Center for Health Statistics; 2005. Accessed at wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes03-04.aspx on 14 March 2016.
20. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: NHANES 2005-2006. Hyattsville, MD: National Center for Health Statistics; 2007. Accessed at wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes05-06.aspx on 14 March 2016.
21. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: NHANES 2007-2008. Hyattsville, MD: National Center for Health Statistics; 2009. Accessed at wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes07-08.aspx on 14 March 2016.
22. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: NHANES 2009-2010. Hyattsville, MD: National Center for Health Statistics; 2011. Accessed at wwwn.cdc.gov/Nchs/Nhanes/Search/nhanes09-10.aspx on 14 March 2016.
23. National Center for Health Statistics. National Health Interview Survey: 2007 data release. Hyattsville, MD: National Center for Health Statistics; 2008. Accessed at www.cdc.gov/nchs/nhis/nhis-2007-data-release.htm on 14 March 2016.
24. Congressional Budget Office. Raising the excise tax on cigarettes: effects on health and the federal budget. Washington, DC: Congressional Budget Office; 2012. Accessed at www.cbo.gov/publication/43319 on 14 March 2016.
25. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Costeffectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
26. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405-10. [PMID: 19293073]
27. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303:841-8. [PMID: 20197530] doi: 10.1001/jama.2010.221
28. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
29. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134-41.[PMID: 18997198] doi: 10.1001/jama.2008.623
30. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group. The Prevention Of Progression of Arterial Disease And Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. [PMID: 18927173] doi: 10.1136/bmj.a1840
31. de Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001;357:89-95. [PMID: 11197445]
32. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet. 1998;351:233-41. [PMID: 9457092]
33. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352:1293-304. [PMID: 15753114]
34. Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312: 2510-20. [PMID: 25401325] doi: 10.1001/jama.2014.15690
35. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternateday, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77-85. [PMID: 23856681] doi: 10.7326/0003-4819-159-2-201307160-00002
36. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007;369:1603-13. [PMID: 17499602]
37. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet. 2012;380:2129-43. [PMID: 23245605] doi: 10.1016/S0140-6736(12)61680-8
38. Nyman JA, Barleen NA, Dowd BE, Russell DW, Coons SJ, Sullivan PW. Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics. Med Care. 2007;45:618-28. [PMID: 17571010]
39. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736-49. [PMID: 15970790]
40. Mittmann N, Trakas K, Risebrough N, Liu BA. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics. 1999;15:369-76. [PMID: 10537955]
41. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. [PMID: 8483408]
42. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Costeffectiveness in Health and Medicine. New York: Oxford Univ Pr 1996.
43. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410-20. [PMID: 16855129]
44. Ko CY, Maggard M, Livingston EH. Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res. 2003; 114:1-5. [PMID: 13678691]
45. Djalalov S, Rabeneck L, Tomlinson G, Bremner KE, Hilsden R, Hoch JS. A review and meta-analysis of colorectal cancer utilities. Med Decis Making. 2014;34:809-818. [PMID: 24903121]
46. Lee HY, Hwang JS, Jeng JS, Wang JD. Quality-adjusted life expectancy (QALE) and loss of QALE for patients with ischemic stroke and intracerebral hemorrhage: a 13-year follow-up. Stroke. 2010;41: 739-44. [PMID: 20150543] doi: 10.1161/STROKEAHA.109.573543
47. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286-94. [PMID: 22706834] doi: 10.1001/jama.2012.5034
48. Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. BMJ. 1995;311:222-6. [PMID: 7627034]
49. National Cancer Institute; Surveillance Research Program. SEER∗Stat, version 8.1.5. Bethesda, MD: National Cancer Institute; 2014.
50. Centers for Disease Control and Prevention. Smoking- Attributable Mortality, Morbidity, and Economic Costs (SAMMEC): Adult SAMMEC and Maternal and Child Health (MCH) SAMMEC software. Atlanta, GA: Centers for Disease Control and Prevention; 2007.
51. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD; ISPOR-SMDM Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32:722-32. [PMID: 22990087]
52. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Evidence Synthesis No 131. AHRQ Publication No. 15-05229-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015. [PMID: 26491755]
53. van Kruijsdijk RC, Visseren FL, Ridker PM, Dorresteijn JA, Buring JE, van der Graaf Y, et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart. 2015;101:369-76. [PMID: 25475110] doi: 10.1136/heartjnl-2014-306342
54. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26:47-57. [PMID: 25096604] doi: 10.1093/annonc/mdu225
55. Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med. 2013;28:1483-91. [PMID: 23681842] doi: 10.1007/s11606-013-2465-6
56. Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H, et al; Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging. 2003;20:897-903. [PMID: 14565783]